Ascendis Pharma A/S - American Depositary Shares (ASND)
129.41
0.00 (0.00%)
Ascendis Pharma is a biotechnology company focused on developing innovative medicines using its proprietary TransCon technology platform
The company aims to address unmet medical needs, particularly in the areas of endocrine diseases and rare disorders, by creating optimally dosed therapies that enhance the bioavailability and efficacy of existing therapies. Through its robust pipeline, Ascendis Pharma is committed to advancing new treatment options that improve patient outcomes and quality of life, leveraging its expertise in drug development and deep understanding of biological mechanisms.
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (NASDAQASND), Alvotech SA NASDAQ: ALVONASDAQALVO)(NYSE: FOURNYSEFOUR, and Waldencast Plc (NASDAQ: WALDNASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors.
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against C3.ai, Inc. (NYSEAI), Ascendis Pharma A/S NASDAQ: ASNDNASDAQASND)(NASDAQ: ALVONASDAQALVO, and Shift4 Payments, Inc. (NYSE: FOURNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Ascendis Pharma A/S (NASDAQASND), and Shift4 Payments, Inc. NYSE: FOURNYSEFOUR)
San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQASND) on behalf of Ascendis stockholders. Our investigation concerns whether Ascendis has violated the federal securities laws and/or engaged in other unlawful business practices.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQASND). Investors who purchased Ascendis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/asnd.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ascendis Pharma A/S (“Ascendis” or “the Company”) (NASDAQASND) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ascendis Pharma A/S (“Ascendis” or “the Company”) (NASDAQASND) for violations of the securities laws.
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Ascendis Pharma (NASDAQASND) resulting from allegations that Ascendis may have issued materially misleading business information to the investing public.
